Real-world use of the CarestartTM glucose-6-phosphate dehydrogenase rapid diagnostic test to determine G6PD deficiency in Nigerian neonates
Journal of Tropical Pediatrics · 2024
DOI: 10.1093/tropej/fmae050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Tropical Pediatrics, 2024. Verfasst von Ejiroghene Orubu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Minnesota, Minneapolis, MN, 55414, United States. Hauptthemen laut MEDLINE: Glucosephosphate Dehydrogenase Deficiency, Neonatal Screening. Die Arbeit nennt 20 Literaturangaben. Gefördert von: NGO Medicine for Sick Children.
Abstract (Originalsprache)
G6PD deficiency (G6PDd) is the most common X-linked genetic disease worldwide and the most common cause of severe neonatal hyperbilirubinemia (NH) in Nigeria. Screening for G6PDd has been recommended for over thirty years but is still not routinely done in Nigeria. We sought to investigate a low-cost rapid diagnostic test to determine G6PDd in Nigerian neonates. Enrolled neonates were screened using the CareStartTM G6PD point-of-care rapid diagnostic test; and mothers/caregivers of neonates with G6PDd were asked about their cord care product(s); transcutaneous bilirubin levels were done on neonates with G6PDd using the JM 103 meter. One hundred and forty neonates were enrolled between 15 January and 1 July 2022. Eighteen (12.8%) of all neonates enrolled and 13.9% of enrolled males (0% of females) were G6PDd. Seventeen of the mothers/caregivers of the G6PDd neonates were asked about cord care. The majority of mothers/caregivers (15/17, 88%%) reported including methylated spirits in their neonate’s cord care; seven of these used chlorohexidine plus methylated spirits (41.2%) while only one mother/caregiver used chlorohexidine alone. One mother/caregiver used mentholatum alone and another used mentholatum, chlorhexidine gel, and methylated spirits. Maximum bilirubin levels for those infants with G6PDd ranged from 3.2 to 18.8 mg/dl with 16/17 (94.1%) of bilirubin levels exceeding 5.5 mg/dl. This study again highlights the need for large-scale G6PDd screening. Additionally, it highlights the need to correlate the type of cord care with the risk of NH in future studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of Minnesota, Minneapolis, MN, 55414, United States.
- Department of Paediatrics, College of Medicine, University of Lagos, Lagos, 102215, Nigeria.
- Department of Pediatrics, Hennepin Healthcare, Minneapolis, MN, 55414, United States.
ORCID-Profile: Tina Slusher
Förderung
- NGO Medicine for Sick Children
Zitieren
APA
Orubu, E., Satrom, K., Ezenwa, B., Fajolu, I., Lund, T., Obi, A., Ezeaka, C., & Slusher, T. (2024). Real-world use of the CarestartTM glucose-6-phosphate dehydrogenase rapid diagnostic test to determine G6PD deficiency in Nigerian neonates. Journal of Tropical Pediatrics. https://doi.org/10.1093/tropej/fmae050
Vancouver
Orubu E, Satrom K, Ezenwa B, Fajolu I, Lund T, Obi A, et al. Real-world use of the CarestartTM glucose-6-phosphate dehydrogenase rapid diagnostic test to determine G6PD deficiency in Nigerian neonates. Journal of Tropical Pediatrics. 2024. doi:10.1093/tropej/fmae050
BibTeX
@article{Orubu2024,
author = {Orubu, Ejiroghene and Satrom, Katherine and Ezenwa, Beatrice and Fajolu, Iretiola and Lund, Troy and Obi, Abigail and Ezeaka, Chinyere and Slusher, Tina},
title = {Real-world use of the CarestartTM glucose-6-phosphate dehydrogenase rapid diagnostic test to determine G6PD deficiency in Nigerian neonates},
journal = {Journal of Tropical Pediatrics},
year = {2024},
doi = {10.1093/tropej/fmae050}
}
EUVIMED